Newswise — An international team, led by researchers at the University of California San Diego School of Medicine, has developed and validated a genetic tool for predicting age of onset of aggressive prostate cancer, a disease that kills more than 26,000 American men annually.
The tool, described in the January 11 online issue of the BMJ (formerly the British Medical Journal), may potentially be used to help guide decisions about who to screen for prostate cancer and at what age.
Currently, detection of prostate cancer relies primarily upon the prostate-specific antigen (PSA) screening blood test. But PSA testing is not very good as a screening tool. While it reduces deaths from prostate cancer, indiscriminate PSA screening also produces false positive results and encourages over-detection of non-aggressive, slow-growing tumors.
“The existing PSA test is useful, but it is not precise enough to be used indiscriminately on all men,” said the study’s first author, Tyler M. Seibert, MD, PhD, chief resident physician in the Department of Radiation Medicine and Applied Sciences at UC San Diego School of Medicine. “As a result, it may prompt medical interventions like biopsy, surgery or radiotherapy that might not be necessary.”
Seibert, senior author Anders Dale, PhD, professor and co-director of the Center for Translational Imaging and Precision Medicine at UC San Diego School of Medicine, and colleagues in Europe, Australia and the United States, used genome-wide association studies (GWAS) to determine whether a man’s genetic predisposition to developing prostate cancer could be used to predict his risk of developing the aggressive and lethal form of the disease.
GWAS search individual genomes for small variations, called single-nucleotide polymorphisms (SNPs), that occur more frequently in people with a particular disease than in people without the disease. Hundreds or thousands of SNPs can be evaluated at the same time in large groups of people. In this case, researchers used data from over 200,000 SNPs from 31,747 men of European ancestry participating in the ongoing international PRACTICAL consortium project.
Using a method developed at UC San Diego, the researchers combined information from GWAS and epidemiological surveys to assess quantification for genetic risk at age of disease onset. “Polygenic Hazard Score methodology is specialized in finding age-dependent genetic risks and has already been proven to be very useful in predicting age of onset for Alzheimer’s disease”, said study co-author Chun Chieh Fan, MD, PhD, in the Department of Cognitive Science at UC San Diego.
“The polygenic hazard score is very versatile and can be applied to many age-related diseases,” said Fan. “In this case, the polygenic hazard score of prostate cancer captures the age variations of aggressive prostate cancer.”
Genotype, prostate cancer status and age were analyzed to select SNPs associated with prostate cancer diagnosis. Then the data was incorporated into the polygenic hazard score, which involves survival analysis to estimate SNPs’ effects on age at diagnosis of aggressive prostate cancer. The results led to a polygenic hazard score for prostate cancer that can estimate individual genetic risk. This score was then tested against an independent dataset, from the recent UK ProtecT trial, for validation.
“The polygenic hazard score was calculated from 54 SNPs and proved to be a highly significant predictor of age at diagnosis of aggressive prostate cancer,” said Seibert. “When men in the ProtecT dataset with a high polygenic hazard score were compared to those with average PHS, their risk of aggressive prostate cancer was at least 2.9 times greater.”
“And when we account statistically for the effect of the GWAS having disproportionately high numbers of men with disease compared to the general population, we estimate that the risk defined by the polygenic hazard score is 4.6 times greater.”
The study authors note that an individual’s genotype does not change with age, so the polygenic hazard score can be calculated at any time and used as a tool for men deciding whether and when to undergo screening for prostate cancer. This is especially critical for men at risk of developing prostate cancer at a very young age, before standard guidelines recommend consideration of screening.
“This kind of genetic risk stratification is a step toward individualized medicine,” said Dale, who also noted that PSA tests are much more predictive of aggressive prostate cancer in men with high polygenic hazard score than in those with low polygenic hazard score. This suggests that polygenic hazard score can help physicians determine whether to order a PSA test for a given patient, in the context of the patient’s general health and other risk factors.
Investigators caution that further study of the clinical benefits are needed before the polygenic hazard score is ready for routine use.
Co-authors of this study include: Chun Chieh Fan, Roshan Karunamuni, J. Kellogg Parsons and David S. Karow, UCSD; Yunpeng Wang, Ole A. Andreassen, University of Oslo; Verena Zuber, University of Oslo and MRC Biostatistics Unit, Cambridge, UK; Rosalind A. Eeles, the Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK; Douglas F. Easton, Centre for Cancer Genetic Epidemiology, UK; Zsofia Kote-Jarai, The Institute of Cancer Research, UK; Ali Amin Al Olama, Sara Benlloch Garcia, Paul Pharoah and Kay-Tee Khaw, University of Cambridge, UK; Kenneth Muir, University of Manchester and University of Warwick, UK; Henrik Grönberg, Fredrik Wiklund and Markus Aly, Karolinska Institutet, Sweden; Johanna Schleutker, University of Turku and University of Tampere, Finland; Csilla Sipeky, University of Turku; Teuvo L.J. Tammela, University of Tampere; Børge G. Nordestgaard and Sune F. Nielsen, University of Copenhagen, Denmark; Maren Weischer, M. Andreas Røder and Peter Iversen, Copenhagen University Hospital; Rasmus Bisbjerg, Copenhagen University; Tim J. Key, Ruth C. Travis, David E. Neal and Freddie C. Hamdy, University of Oxford, UK; Jenny L. Donovan, University of Bristol, UK; Nora Pashayan, University of Cambridge and University College London, UK; Christiane Maier, Walther Vogel and Manuel Luedeke, University Hospital of Ulm, Germany; Kathleen Herkommer, Klinikum rechts der Isar der Technischen Universitaet, Germany; Adam S. Kibel, Dana-Farber Cancer Institute, Boston; Cezary Cybulski, Dominika Wokolorczyk and Wojciech Kluzniak, Pomeranian Medical University, Poland; Lisa Cannon-Albright, University of Utah and George E. Wahlen Department of Veterans Affairs Medical Center; Hermann Brenner, Katarina Cuk and Kai-Uwe Saum, German Cancer Research Center, Germany; Jong Y. Park and Thomas A. Sellers, Moffitt Cancer Center, Tampa; Chavdar Slavov, Radka Kaneva and Vanio Mitev, Medical University, Bulgaria; Jyotsna Batra, Judith A. Clements, Amanda Spurdle, Queensland University of Technology, Australia; Manuel R. Teixeira, Paula Paulo and Sofia Maia, University of Porto, Portugal; Hardev Pandha, Agnieszka Michael and Andrzej Kierzek, University of Surrey, UK; Ian G. Mills, University of Oslo, Queens University Belfast and University of Oxford; and the PRACTICAL consortium.
Funding for this research came, in part, from the U.S. Department of Defense (w81xwh-13-1-0391), the Prostate Cancer Foundation, the Research Council of Norway, KG Jebsen Stiftelsen and South East Norway Health Authority.